Literature DB >> 28343650

[Surveillance system on drug abuse: Interest of the French national OPPIDUM program of French addictovigilance network].

Elisabeth Frauger1, Liselotte Pochard2, Quentin Boucherie2, Adeline Giocanti2, Cécile Chevallier3, Amélie Daveluy4, Valérie Gibaja5, Anne-Sylvie Caous6, Céline Eiden7, Nicolas Authier8, Reynald Le Boisselier9, Marylène Guerlais10, Émilie Jouanjus11, Marion Lepelley12, Véronique Pizzoglio13, Stéphanie Pain14, Nathalie Richard15, Joëlle Micallef2.   

Abstract

It is important to assess drug abuse liability in 'real life' using different surveillance systems. OPPIDUM ('Observation of illegal drugs and misuse of psychotropic medications') surveillance system anonymously collects information on drug abuse and dependence observed in patients recruited in specialized care centers dedicated to drug dependence. The aim of this article is to demonstrate the utility of OPPIDUM system using 2015 data. OPPIDUM is a cross-sectional survey repeated each year since 1995. In 2015, 5003 patients described the modality of use of 10,159 psychoactive drugs. Among them, 77% received an opiate maintenance treatment: 68% methadone (half of them consumed capsule form) and 27% buprenorphine (39% consumed generic form). Brand-name buprenorphine is more often injected than generic buprenorphine (10% vs. 2%) and among methadone consumers 7% of methadone capsule consumers have illegally obtained methadone (vs. 9% for syrup form). The proportion of medications among psychoactive drugs injected is important (42%), with morphine representing 21% of the total psychoactive drugs injected and buprenorphine, 16%. OPPIDUM highlighted emergent behaviors of abuse with some analgesic opioids (like tramadol, oxycodone or fentanyl), pregabalin, or quetiapine. OPPIDUM highlighted variations of drugs use regarding geographic approaches or by drug dependence care centers (like in harm reduction centers). OPPIDUM clearly demonstrated that collection of valid and useful data on drug abuse is possible, these data have an interest at regional, national and international levels.
Copyright © 2017 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Abus de substances psychoactives; Dispositifs de surveillance et de veille sanitaire; Pharmacoepidemiology; Pharmacoépidémiologie; Postmarketing surveillance system; Prescription drug abuse; Substance-related disorders

Mesh:

Year:  2017        PMID: 28343650     DOI: 10.1016/j.therap.2017.01.010

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  9 in total

1.  A comparative study of QT prolongation with serotonin reuptake inhibitors.

Authors:  Ana Ojero-Senard; Justine Benevent; Emmanuelle Bondon-Guitton; Geneviève Durrieu; Leila Chebane; Melanie Araujo; Francois Montastruc; Jean-Louis Montastruc
Journal:  Psychopharmacology (Berl)       Date:  2017-08-03       Impact factor: 4.530

Review 2.  Interpol review of controlled substances 2016-2019.

Authors:  Nicole S Jones; Jeffrey H Comparin
Journal:  Forensic Sci Int Synerg       Date:  2020-05-24

3.  A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019).

Authors:  Joelle Perri-Plandé; Ghada Miremont-Salamé; Joëlle Micallef; Cameron Herman; Marie Baumevieille; Frédéric Abriat; Maryse Lapeyre-Mestre; Françoise Haramburu; Amélie Daveluy
Journal:  Drug Saf       Date:  2021-10-29       Impact factor: 5.606

4.  Intentional Drug Overdose Involving Pregabalin and Gabapentin: Findings from the National Self-Harm Registry Ireland, 2007-2015.

Authors:  Caroline Daly; Eve Griffin; Darren M Ashcroft; Roger T Webb; Ivan J Perry; Ella Arensman
Journal:  Clin Drug Investig       Date:  2018-04       Impact factor: 2.859

5.  Identification and Characterization of Biomarkers and Their Role in Opioid Addiction by Integrated Bioinformatics Analysis.

Authors:  Xiuning Zhang; Hailei Yu; Rui Bai; Chunling Ma
Journal:  Front Neurosci       Date:  2020-11-27       Impact factor: 4.677

6.  Increase of high-risk tramadol use and harmful consequences in France from 2013 to 2018: Evidence from the triangulation of addictovigilance data.

Authors:  Anne Roussin; Thomas Soeiro; Charlotte Fouque; Emilie Jouanjus; Elisabeth Frauger; Nathalie Fouilhé; Michel Mallaret; Joëlle Micallef; Maryse Lapeyre-Mestre
Journal:  Br J Clin Pharmacol       Date:  2022-04-05       Impact factor: 3.716

Review 7.  Early Detection of Prescription Drug Abuse Using Doctor Shopping Monitoring From Claims Databases: Illustration From the Experience of the French Addictovigilance Network.

Authors:  Thomas Soeiro; Clémence Lacroix; Vincent Pradel; Maryse Lapeyre-Mestre; Joëlle Micallef
Journal:  Front Psychiatry       Date:  2021-05-17       Impact factor: 4.157

Review 8.  Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review.

Authors:  Fabrizio Schifano; Stefania Chiappini; John M Corkery; Amira Guirguis
Journal:  Brain Sci       Date:  2018-04-22

9.  Pregabalin Abuse in Combination With Other Drugs: Monitoring Among Methadone Patients.

Authors:  Massimo Lancia; Angela Gambelunghe; Alessio Gili; Mauro Bacci; Kyriaki Aroni; Cristiana Gambelunghe
Journal:  Front Psychiatry       Date:  2020-02-11       Impact factor: 4.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.